- Title
- Acute radiation skin toxicity associated with BRAF inhibitors
- Creator
- Pulvirenti, T.; Hong, A.; Long, G. V.; Wang, W.; Clements, A.; Forstner, D.; Suchowersky, A.; Guminski, A.; McNeil, C.; Hersey, P.; Fogarty, G.; Kefford, R.
- Relation
- Journal of Clinical Oncology Vol. 34, Issue 3, p. e17-e20
- Publisher Link
- http://dx.doi.org/10.1200/JCO.2013.49.0565
- Publisher
- American Society of Clinical Oncology
- Resource Type
- journal article
- Date
- 2016
- Description
- BRAF inhibitors, vemurafenib and dabrafenib, are the mainstay of treatmentfor BRAF-mutant metastatic melanoma. Cutaneous toxicities are themostfrequent adverse effects, particularly hyperkeratosis (6% to 51% with vemurafenib), as well as cutaneous squamous cell carcinoma and keratoacanthoma (4.3% to 31% with vemurafenib, 6% to 11% with dabrafenib).1 Photosensitivity can occur in 52% of patients treated with vemurafenib. Radiation therapy plays an important role in the treatment of patients with metastatic melanoma. In this report, we describe five patients who experienced unanticipated increased in-field skin toxicity while undergoing radiotherapy with the concomitant use of BRAF inhibitors.
- Subject
- vemurafenib; dabrafenib; BRAF-mutant metastatic melanoma; radiation theraphy
- Identifier
- http://hdl.handle.net/1959.13/1319013
- Identifier
- uon:23758
- Identifier
- ISSN:0732-183X
- Language
- eng
- Hits: 8110
- Visitors: 8094
- Downloads: 0
Thumbnail | File | Description | Size | Format |
---|